Cargando…

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer

Lung cancer remains the leading cause of cancer-related death with an incidence that continues to increase in both sexes and all ages. However, 80% to 90% of lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% are small cell lung cancer. Adenocarcinoma is the most common...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baudoux, Nathalie, Friedlaender, Alex, Addeo, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932776/ https://www.ncbi.nlm.nih.gov/pubmed/36818454 http://dx.doi.org/10.1177/11795549231152948

Ejemplares similares

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
por: Perdrizet, Kirstin, et al.
Publicado: (2021)

COVID-19 and lung cancer: risks, mechanisms and treatment interactions
por: Addeo, Alfredo, et al.
Publicado: (2020)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
por: Mederos, Nuria, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

Therapeutic management options for stage III non-small cell lung cancer
por: Yoon, Stephanie M, et al.
Publicado: (2017)

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
por: Friedlaender, Alex, et al.
Publicado: (2019)

1393P Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy
por: Banna, G.L., et al.
Publicado: (2020)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era
por: Li, Jiakang, et al.
Publicado: (2022)

Mismatch repair deficiency in rectal cancer: an evolving scenario
por: Longo, Federico, et al.
Publicado: (2022)

Home-deliverable antitumoral treatments in the age of COVID-19: the Portsmouth experience and a narrative review
por: Mechahougui, Hiba, et al.
Publicado: (2022)

Tracking the tail
por: Friedlaender, Alex, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Stepping in the right direction but still some ways to go
por: Addeo, Alfredo, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature Review
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer
por: Terakedis, Breanne, et al.
Publicado: (2011)

Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients
por: Urvay, Semiha Elmaci, et al.
Publicado: (2016)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Induction treatment in patients with stage III non-small cell lung cancer
por: Palmero, Ramón, et al.
Publicado: (2021)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Unanticipated Radiation Replanning for Stage III Non-small Cell Lung Cancer
por: Mushonga, Melinda, et al.
Publicado: (2023)

The evolving role of radiotherapy in non-small cell lung cancer
por: Brown, Sean, et al.
Publicado: (2019)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Cancer and COVID-19: Unmasking their ties
por: Addeo, A., et al.
Publicado: (2020)

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review
por: Thouvenin, Laure, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oko08t5qf817h7loc3rk7sa9ar